208 related articles for article (PubMed ID: 23433326)
1. Prevention of preterm birth by progestational agents: what are the molecular mechanisms?
Nold C; Maubert M; Anton L; Yellon S; Elovitz MA
Am J Obstet Gynecol; 2013 Mar; 208(3):223.e1-7. PubMed ID: 23433326
[TBL] [Abstract][Full Text] [Related]
2. Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.
Furcron AE; Romero R; Plazyo O; Unkel R; Xu Y; Hassan SS; Chaemsaithong P; Mahajan A; Gomez-Lopez N
Am J Obstet Gynecol; 2015 Dec; 213(6):846.e1-846.e19. PubMed ID: 26264823
[TBL] [Abstract][Full Text] [Related]
3. miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor.
Renthal NE; Chen CC; Williams KC; Gerard RD; Prange-Kiel J; Mendelson CR
Proc Natl Acad Sci U S A; 2010 Nov; 107(48):20828-33. PubMed ID: 21079000
[TBL] [Abstract][Full Text] [Related]
4. 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: A randomized controlled trial.
Pirjani R; Heidari R; Rahimi-Foroushani A; Bayesh S; Esmailzadeh A
J Obstet Gynaecol Res; 2017 Jan; 43(1):57-64. PubMed ID: 27775195
[TBL] [Abstract][Full Text] [Related]
5. Replens prevents preterm birth by decreasing type I interferon strengthening the cervical epithelial barrier.
Nold C; Jensen T; O'Hara K; Stone J; Yellon SM; Vella AT
Am J Reprod Immunol; 2020 Jan; 83(1):e13192. PubMed ID: 31549469
[TBL] [Abstract][Full Text] [Related]
6. How does progesterone relax the uterus in pregnancy?
Zakar T; Mesiano S
N Engl J Med; 2011 Mar; 364(10):972-3. PubMed ID: 21388317
[No Abstract] [Full Text] [Related]
7. N-acetylcysteine prevents preterm birth by attenuating the LPS-induced expression of contractile associated proteins in an animal model.
Chang EY; Zhang J; Sullivan S; Newman R; Singh I
J Matern Fetal Neonatal Med; 2012 Nov; 25(11):2395-400. PubMed ID: 22676250
[TBL] [Abstract][Full Text] [Related]
8. The microRNA (miR)-199a/214 cluster mediates opposing effects of progesterone and estrogen on uterine contractility during pregnancy and labor.
Williams KC; Renthal NE; Gerard RD; Mendelson CR
Mol Endocrinol; 2012 Nov; 26(11):1857-67. PubMed ID: 22973051
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016.
Goodnight W
Am J Perinatol; 2016 Feb; 33(3):253-7. PubMed ID: 26788788
[TBL] [Abstract][Full Text] [Related]
10. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
11. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
Facchinetti F; Vergani P; Di Tommaso M; Marozio L; Acaia B; Vicini R; Pignatti L; Locatelli A; Spitaleri M; Benedetto C; Zaina B; DʼAmico R
Obstet Gynecol; 2017 Jul; 130(1):64-70. PubMed ID: 28594783
[TBL] [Abstract][Full Text] [Related]
12. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length.
Berghella V; Figueroa D; Szychowski JM; Owen J; Hankins GD; Iams JD; Sheffield JS; Perez-Delboy A; Wing DA; Guzman ER;
Am J Obstet Gynecol; 2010 Apr; 202(4):351.e1-6. PubMed ID: 20350641
[TBL] [Abstract][Full Text] [Related]
13. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
[TBL] [Abstract][Full Text] [Related]
14. Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate.
Szychowski JM; Berghella V; Owen J; Hankins G; Iams JD; Sheffield JS; Perez-Delboy A; Wing DA; Guzman ER;
J Matern Fetal Neonatal Med; 2012 Dec; 25(12):2686-9. PubMed ID: 22889234
[TBL] [Abstract][Full Text] [Related]
15. The effect of 17α-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage.
Rafael TJ; Mackeen AD; Berghella V
Am J Perinatol; 2011 May; 28(5):389-94. PubMed ID: 21380984
[TBL] [Abstract][Full Text] [Related]
16. Optimal routes of administration, vehicles and timing of progesterone treatment for inhibition of delivery during pregnancy.
Fang D; Moreno M; Garfield RE; Kuon R; Xia H
Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():164-168. PubMed ID: 28777967
[TBL] [Abstract][Full Text] [Related]
17. The association of different progesterone preparations with preterm birth prevention.
Krispin E; Hadar E; Chen R; Wiznitzer A; Kaplan B
J Matern Fetal Neonatal Med; 2019 Oct; 32(20):3452-3457. PubMed ID: 29699436
[No Abstract] [Full Text] [Related]
18. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
Facchinetti F; Vaccaro V
Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
[TBL] [Abstract][Full Text] [Related]
19. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial.
Senat MV; Porcher R; Winer N; Vayssière C; Deruelle P; Capelle M; Bretelle F; Perrotin F; Laurent Y; Connan L; Langer B; Mantel A; Azimi S; Rozenberg P;
Am J Obstet Gynecol; 2013 Mar; 208(3):194.e1-8. PubMed ID: 23433324
[TBL] [Abstract][Full Text] [Related]
20. Rationale for current and future progestin-based therapies to prevent preterm birth.
Weatherborn M; Mesiano S
Best Pract Res Clin Obstet Gynaecol; 2018 Oct; 52():114-125. PubMed ID: 29724668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
